Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Neoantigen

In one sentence

A neoantigen is an immune-recognition target arising from a tumor-specific sequence alteration.

The intuition

A changed sentence may create a new fragment a reader can notice. The tumor alteration is the source; the displayed fragment is the potential target. A real spelling change does not guarantee that anyone sees it. Likewise, a mutation alone does not demonstrate immune recognition.

How it works

A DNA substitution, insertion, deletion or rearrangement can change a protein sequence. Altered RNA splicing can also create candidate sequences. A candidate must be expressed and processed before a conventional T cell can inspect it as a peptide displayed by human leukocyte antigen (HLA).

The T-cell receptor recognizes the combined peptide–HLA surface. Different HLA alleles can present different fragments from the same altered sequence. One tumor alteration can therefore yield several candidate targets, or none that are useful.

Studies sometimes call predicted candidates “neoantigens” before recognition has been measured. Record whether the claim is sequence prediction, binding, measured presentation or an antigen-specific functional response. These are distinct evidence levels.

Why it matters in cancer

Personalized vaccines and some engineered receptors pursue tumor-specific targets. Candidate selection must consider expression, tumor coverage, presentation, recognition and healthy-tissue cross-reactivity.

Worked example

A fictional mutation has strong RNA support and predicted HLA binding. It is a plausible candidate. A negative tumor-recognition experiment could reflect poor display, the tested receptor or assay conditions. The sequence finding remains real while the therapeutic claim remains unproved.

Common confusions

  • Tumor-specific sequence does not guarantee immune recognition or safety.
  • A tumor-associated antigen can also occur in normal tissue.
  • More predicted targets do not necessarily mean broader effective coverage.

Sources and scope

Source check: October 8, 2026. This is a mechanism explanation, not a treatment recommendation. Expert and learner review remain pending.

Used in